Imaging in Cardio-Oncology: Role of Novel Echo Parameters in Breast Cancer and Gynecologic Malignancies.

PURPOSE OF REVIEW: To review the use of echocardiography in monitoring for cardiotoxicity in women with breast or gynecologic cancer. RECENT FINDINGS: Left ventricular ejection fraction (LVEF) is a mainstay of monitoring for cancer treatment related cardiotoxicity (CTRCD). Three-dimensional volumetric LVEF is recommended over other LVEF assessments like Simpson’s biplane. Studies have shown that changes in global longitudinal strain (GLS) may indicate subclinical cardiotoxicity. Diastolic function, right ventricular function, myocardial work, left atrial strain, and stress testing all have emerging roles in monitoring for cardiotoxicity. Finally, applications of artificial intelligence in monitoring for CTRCD are discussed. Echocardiography remains a powerful tool for early detection and monitoring of cardiotoxicity associated with cancer therapy. Several novel echocardiography parameters are being investigated and have the potential to further enhance early detection of cardiotoxicity.